{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:34Z","timestamp":1792801714565,"version":"4.5.0"},"reference-count":112,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.<\/jats:p>","DOI":"10.1182\/blood-2011-02-297325","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T04:41:12Z","timestamp":1301460072000},"page":"6063-6073","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":259,"title":["International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation"],"prefix":"10.1182","volume":"117","author":[{"given":"Michele","family":"Cavo","sequence":"first","affiliation":[{"name":"Ser\u00e0gnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Clinic, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Sezer","sequence":"additional","affiliation":[{"name":"University Medical Center, University of Hamburg, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[{"name":"First Medical Department and Medical Oncology, Wilhelminenspital Hospital, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[{"name":"Service of Hematology, Hopital Purpan, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Department of Medicine and Experimental Oncology, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans E.","family":"Johnsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical Center, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kroeger","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Hospital Hamburg, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6sta","family":"Gahrton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Huddinge University Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Wuertzburg University Hospital, Wuertzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mt Sinai Cancer Institute, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Multiple Myeloma, Aptium Oncology, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Centro de Investigaci\u00f3n del C\u00e1ncer, Instituto de Biologia Molecular y Celular del C\u00e1ncer (CIC IBMCC), Universidad de Salamanca-Conscjo Superior de Investigaciones Cientificas (USAL-CSIC), Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111711374981300_B1","unstructured":"Altekruse SF Kosary C Krapcho M Neyman N Aminou R Waldron W SEER Cancer Statistics Review 1975\u20132007 Accessed March 10, 2011 Bethesda, MD National Cancer Institute http:\/\/www.seercancergov\/csr\/1975_2007"},{"issue":"8","key":"2019111711374981300_B2","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111711374981300_B3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111711374981300_B4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1056\/NEJMe058322","article-title":"The changing landscape of myeloma therapy.","volume":"354","author":"Cavo","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111711374981300_B5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111711374981300_B6","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial.","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"9594","key":"2019111711374981300_B7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"2019111711374981300_B8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111711374981300_B9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111711374981300_B10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.2007.11.6863","article-title":"Stem-cell transplantation for multiple myeloma in the era of novel drugs.","volume":"26","author":"Bensinger","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111711374981300_B11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2009.07649.x","article-title":"Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.","volume":"145","author":"Lonial","year":"2009","journal-title":"Br J Haematol"},{"issue":"27","key":"2019111711374981300_B12","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1182\/blood-2009-07-204651","article-title":"How I treat multiple myeloma in younger patients.","volume":"114","author":"Stewart","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111711374981300_B13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111711374981300_B14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111711374981300_B15","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma.","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111711374981300_B16","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"issue":"36","key":"2019111711374981300_B17","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111711374981300_B18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111711374981300_B19","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111711374981300_B20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis.","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111711374981300_B21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111711374981300_B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.614.614","article-title":"Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis [abstract].","volume":"114","author":"Mateos","year":"2009","journal-title":"Blood"},{"key":"2019111711374981300_B23","unstructured":"National Cancer Comprehensive Network NCCN Clinical practice guidelines in oncology: multiple myeloma. Accessed March 10, 2011 http:\/\/wwwnccnorg\/professionals\/physician_gls\/PDF\/myelomapdf"},{"issue":"6","key":"2019111711374981300_B24","first-page":"717","article-title":"Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).","volume":"89","author":"Barosi","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"2019111711374981300_B25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005.","volume":"132","author":"Smith","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111711374981300_B26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.","volume":"13","author":"Koreth","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111711374981300_B27","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"6","key":"2019111711374981300_B28","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","article-title":"Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.","volume":"101","author":"Segeren","year":"2003","journal-title":"Blood"},{"key":"2019111711374981300_B29","article-title":"High dose therapy supported with autologous blood stem cell transplantation in multiple myeloma: long term follow-up of the prospective studies of the MAG group [abstract].","volume":"90","author":"Fermand","year":"2005","journal-title":"Haematologica"},{"key":"2019111711374981300_B30","article-title":"Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract].","volume":"90","author":"Goldschmidt","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"2019111711374981300_B31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.","volume":"101","author":"Kumar","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"2019111711374981300_B32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jnci\/djp126","article-title":"Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.","volume":"101","author":"Giralt","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"2019111711374981300_B33","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/jnci\/djp320","article-title":"Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.","volume":"101","author":"Mehta","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2019111711374981300_B34","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and the University of Arkansas for Medical Sciences.","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111711374981300_B35","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma.","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2019111711374981300_B36","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.","volume":"28","author":"Chanan-Khan Giralt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111711374981300_B37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"2019111711374981300_B38","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111711374981300_B39","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111711374981300_B40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.23546","article-title":"Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.","volume":"113","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"2019111711374981300_B41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2006.06441.x","article-title":"Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.","volume":"136","author":"Pineda-Roman","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111711374981300_B42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2019111711374981300_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.57.57","article-title":"Dexamethasone + thalidomide (Dex\/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial [abstract].","volume":"108","author":"Macro","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111711374981300_B44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111711374981300_B45","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2009.22.7389","article-title":"Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes compared with double autotransplantation for multiple myeloma.","volume":"27","author":"Cavo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111711374981300_B46","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma.","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111711374981300_B47","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111711374981300_B48","article-title":"MRC Myeloma IX: preliminary results from the intensive pathway study [abstract].","volume":"9","author":"Owen","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"21","key":"2019111711374981300_B49","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111711374981300_B50","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111711374981300_B51","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"issue":"28","key":"2019111711374981300_B52","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.","volume":"25","author":"Rosinol","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111711374981300_B53","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111711374981300_B54","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111711374981300_B55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.40.40","article-title":"HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma [abstract].","volume":"116","author":"Sonneveld","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111711374981300_B56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3618.3618","article-title":"Bortezomib [VELCADE], pegylated liposomal doxorubicin [DOXIL\/CAELYX] and dexamethasone in the treatment of previously untreated multiple myeloma patients: impact on quality-of-life [abstract].","volume":"110","author":"Belch","year":"2007","journal-title":"Blood"},{"issue":"30","key":"2019111711374981300_B57","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111711374981300_B58","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"2019111711374981300_B59","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.131.131","article-title":"Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial) [abstract].","volume":"114","author":"Einsele","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111711374981300_B60","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10245330701214236","article-title":"Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.","volume":"12","author":"Wang","year":"2007","journal-title":"Hematology"},{"issue":"9758","key":"2019111711374981300_B61","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib, thalidomide and dexamethasone compared with thalidomide and dexamethasone as induction before and consolidation therapy after double autologous stem cell transplantation in newly diagnosed multiple myeloma: results from a randomized phase III study.","volume":"379","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"2019111711374981300_B62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.307.307","article-title":"A phase III PETHEMA\/GEM study of induction therapy prior autologous stem cell transplantation in multiple myeloma: superiority of VTD (bortezomib\/thalidomide\/dexamethasone) over TD and VBMCP\/VBAD plus bortezomib [abstract].","volume":"116","author":"Rosi\u00f1ol","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111711374981300_B63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.354.354","article-title":"Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) as induction treatment prior to autologous stem-cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM) [abstract].","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2019111711374981300_B64","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/cncr.25143","article-title":"Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma.","volume":"116","author":"Kaufman","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"2019111711374981300_B65","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2141.2009.07981.x","article-title":"Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.","volume":"148","author":"Bensinger","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111711374981300_B66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2312.2312","article-title":"Bortezomib, thalidomide, and dexamethasone (VTD) versus VTD plus cyclophosphamide as induction therapy in previously untreated multiple myeloma patients eligible for HDT-ASCT: a randomized phase 2 trial [abstract].","volume":"114","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111711374981300_B67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","article-title":"Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.","volume":"140","author":"Pineda-Roman","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111711374981300_B68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1179\/102453310X12583347010133","article-title":"Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).","volume":"15","author":"Wang","year":"2010","journal-title":"Hematology"},{"issue":"5","key":"2019111711374981300_B69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111711374981300_B70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.624.624","article-title":"Frontline therapy with bortezomib, lenalidomide and dexamethasone (VRD) followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 phase II study [abstract].","volume":"116","author":"Roussel","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111711374981300_B71","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","article-title":"Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase I results from the multicenter EVOLUTION study.","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"2019111711374981300_B72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.621.621","article-title":"Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multicenter, randomized, phase 2 EVOLUTION study [abstract].","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111711374981300_B73","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed multiple myeloma: updated results of a phase I\/II MMRC trial [abstract].","volume":"114","author":"Jakuboviak","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111711374981300_B74","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111711374981300_B75","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"2019111711374981300_B76","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14) (q13;q32), t(4;14) (p16.3;q32) and \u221217p13 in myeloma patients treated with high-dose therapy.","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111711374981300_B77","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1200\/JCO.2005.04.7506","article-title":"Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.","volume":"24","author":"Cavo","year":"2006","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111711374981300_B78","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) but not outcome of patients with del(17p).","volume":"28","author":"Avet Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111711374981300_B79","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3562.3562","article-title":"Prognostic impact of cytogenetic abnormalities on outcomes of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous stem-cell transplantation: an analysis of 593 patients [abstract].","volume":"116","author":"Zamagni","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111711374981300_B80","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"21","key":"2019111711374981300_B81","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.623.623","article-title":"Thalidomide maintenance significantly improves progression-free survival (PFS) and overall survival (OS) of myeloma patients when effective relapse treatments are used: MRC Myeloma IX results [abstract].","volume":"116","author":"Morgan","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111711374981300_B82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/leu.2009.273","article-title":"Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.","volume":"24","author":"Avet Loiseau","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2019111711374981300_B83","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111711374981300_B84","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2009-01-202010","article-title":"Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.","volume":"114","author":"Kapoor","year":"2009","journal-title":"Blood"},{"issue":"33","key":"2019111711374981300_B85","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111711374981300_B86","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bbmt.2010.02.020","article-title":"Thalidomide-dexamethasone as induction therapy prior to autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.","volume":"16","author":"Tosi","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111711374981300_B87","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111711374981300_B88","first-page":"194","article-title":"Management of thalidomide toxicity.","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"issue":"6","key":"2019111711374981300_B89","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide: a prospective study.","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"2019111711374981300_B90","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1600-0609.2004.00382.x","article-title":"Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.","volume":"74","author":"Tosi","year":"2005","journal-title":"Eur J Haematol"},{"key":"2019111711374981300_B91","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0305-7372(10)70009-8","article-title":"Management of treatment-related adverse events in patients with multiple myeloma.","volume":"36","author":"Mateos","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2019111711374981300_B92","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111711374981300_B93","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0031-1273085","article-title":"Multiple myeloma, venous thromboembolism and treatment related risk of thrombosis.","volume":"37","author":"Zamagni","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"2019111711374981300_B94","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111711374981300_B95","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2019111711374981300_B96","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111711374981300_B97","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111711374981300_B98","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomized trial.","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111711374981300_B99","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"issue":"29","key":"2019111711374981300_B100","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111711374981300_B101","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"issue":"22","key":"2019111711374981300_B102","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.530.530","article-title":"Improved response rate with bortezomib consolidation after high dose melphalan: first results of a Nordic Myeloma Study Group randomized phase III trial [abstract].","volume":"114","author":"Mellqvist","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111711374981300_B103","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.529.529","article-title":"Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the Intergroupe Francophone Du Myelome (IFM 2005 02) [abstract].","volume":"114","author":"Attal","year":"2009","journal-title":"Blood"},{"issue":"21","key":"2019111711374981300_B104","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.42.42","article-title":"Bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as induction and consolidation therapy before and after double autologous transplantation in newly diagnosed multiple myeloma: results from a randomized phase III study [abstract].","volume":"116","author":"Cavo","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111711374981300_B105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.861.861","article-title":"Molecular remission after bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy after double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis [abstract].","volume":"116","author":"Terragna","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111711374981300_B106","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.leu.2404633","article-title":"Maintenance therapy in multiple myeloma.","volume":"21","author":"Mihelic","year":"2007","journal-title":"Leukemia"},{"key":"2019111711374981300_B107","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111711374981300_B108","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.39.39","article-title":"A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma: the NCIC CTG MY.10 trial [abstract].","volume":"116","author":"Stewart","year":"2010","journal-title":"Blood"},{"issue":"32","key":"2019111711374981300_B109","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1200\/JCO.2009.24.0150","article-title":"Thalidomide maintenance in multiple myeloma: certainties and controversies.","volume":"27","author":"Cavo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111711374981300_B110","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.37.37","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation for multiple myeloma: CALGB 100104 [abstract].","volume":"116","author":"McCarthy","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111711374981300_B111","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.310.310","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract].","volume":"116","author":"Attal","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111711374981300_B112","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.312.312","article-title":"A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma [abstract].","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/23\/6063\/1339368\/zh802311006063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/23\/6063\/1339368\/zh802311006063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T18:37:01Z","timestamp":1592419021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/23\/6063\/22251\/International-Myeloma-Working-Group-consensus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,9]]},"references-count":112,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2011,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-297325","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,9]]}}}